Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
The DOI matches its Crossref record.
Abstract
The integrin receptor alphavbeta3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that alphavbeta3 is a critical target downstream from perhaps all angiogcnic factors. Proof-of-principle that alphavbeta3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the alphavbeta3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the alphavbeta3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus alphavbeta3 may prove to be an important target for pharmacological intervention in more than one clinical setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The critical nature of integrin binding to angiogenesis is also noted in other situations such as embryogenesis, where inhibition of b 1 integrins interfere with the development of the embryonic vasculature 63 and in oncology, where integrin inhibitors are employed to inhibit tumor angiogenesis.”
From Interactions between extracellular matrix and growth factors in wound healing (2009) · cites this paper as [64]
Citations
Cited by
Items 201–283 of 283
Yassin, S., Hu, J., Xu, H., Li, C., & Setrerrahmane, S. (2016) · Oncology Reports · doi:10.3892/or.2016.5077 · Cited by 8
68Ga‐labeling of internalizing RGD (iRGD) peptide functionalized with DOTAGA and NODAGA chelators
Satpati, D., Vats, K., Sharma, R., Sarma, H. D., & Dash, A. K. (2020) · Journal of Peptide Science · doi:10.1002/psc.3241 · Cited by 9
(2024) · doi:10.1016/j.omton.2024.200805 · Cited by 8
Wei, Y., Qin, X., Liu, X., Zheng, J., Luan, X., Zhou, Y., Yu, J., & Yuan, S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03256-3 · Cited by 7
Liposomes as Targeted Drug‐Delivery Systems
Mundargi, R. C., Taneja, N., Hadia, J. J., & Khopade, A. J. (2022) · Methods and principles in medicinal chemistry · doi:10.1002/9783527827855.ch4 · Cited by 8
Li, Z., Lü, J., Tang, B., Shi, Y., Hai, L., Guo, L., & Wu, Y. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116704 · Cited by 6
Khodadad, M., Hosseini, S. Y., Shenavar, F., Erfani, N., Bina, S., Ahmadian, S., Fattahi, M. R., & Hajhosseini, R. (2015) · Europe PMC (PubMed Central) · Cited by 6
Small molecules for bone diseases
Masuya, K., & Teno, N. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543771003604729 · Cited by 6
Yoon, S., Yang, H., Ryu, H.-M., Lee, E., Jo, Y., Seo, S., Kim, D., Lee, C. H., Kim, W., Jung, K. H., et al. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.651 · Cited by 7
Morozevich, G. E., Kozlova, N. I., Chubukina, A. N., Eltsov, I. A., & Berman, A. E. (2004) · Biochemistry (Moscow) · doi:10.1023/b:biry.0000033740.76015.47 · Cited by 6
(2009) · Springer eBooks · doi:10.1007/978-3-540-76735-0_15 · Cited by 6
Li, L., Liu, N., Zhang, H., Tao, R., Zhao, S., Chen, Z., Fu, Z., Li, W., Xu, L., Liu, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.848266 · Cited by 6
Escher, R., Cung, T., Stutz, M., Haeberli, A., Djonov, V., Berchtold, P., & Hlushchuk, R. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03251.x · Cited by 5
Subcellular and Dynamic Coordination between Src Activity and Cell Protrusion in Microenvironment
Zhuo, Y., Qian, T., Wu, Y., Seong, J., Gong, Y., Ma, H., Wang, Y., & Lu, S. (2015) · Scientific Reports · doi:10.1038/srep12963 · Cited by 6
Improved synthesis on solid phase of dithiocarbamic cRGD ‐derivative and 99mTc ‐radiolabelling
Caporale, A., Bolzati, C., Incisivo, G. M., Salvarese, N., Grieco, P., & Ruvo, M. (2019) · Journal of Peptide Science · doi:10.1002/psc.3140 · Cited by 5
Zhou, Y., Song, Z., Hu, Q., Ji, X., Zheng, H., Wang, X., & Li, Z. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00655 · Cited by 5
Zhu, J., Yuan, Y., Li, D., Liao, S., Zhou, Y., Wang, Q., Shu, Y., Yan, B., Wei, J., Sun, R., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02299.x · Cited by 5
Koutsilieris, M., Τέντα, Ρ., Tiblalexi, D., Pitulis, N., Sotiriou, E., Lembessis, P., Bogdanos, J., Milathianakis, C., & Sourla, A. (2005) · Springer eBooks · doi:10.1007/1-4020-3414-8_19 · Cited by 5
Pre-treatment 18F-RGD Uptake may Predict Adverse Events during Apatinib Antiangiogenic Therapy
Li, L., Zheng, J., Liu, Z., Huang, Y., Xiao, J., Wang, S., Yu, Q., Zhang, Q., Hu, X., Zhao, W., et al. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.01.002 · Cited by 4
Liang, S., Ma, Y., Guo, J., Guo, R., & Wang, H. (2014) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-014-3689-6 · Cited by 4
Aparajay, P., Madhyastha, H., Altamimi, M. A., Dev, A., Hussain, A., & Bhowmik, S. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03102-x · Cited by 3
Dordoni, F., Scarpi, D., Bianchini, F., Contini, A., & Occhiato, E. G. (2020) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202000634 · Cited by 3
Anti-Angiogenesis and Disintegrins
Swenson, S. D., Minea, R. O., Zidovetzki, S., Helchowski, C. M., Costa, F. K., & Markland, F. S. (2010) · Springer eBooks · doi:10.1007/978-90-481-9295-3_19 · Cited by 3
Inhibition of angiogenesis by a synthetic fusion protein VTF derived from vasostatin and tumstatin
Gu, Q., Cihuang, S., Luo, J., Zhang, T., & Wang, L. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000134 · Cited by 3
Uncilla, N. Z., Miranda, J. I., Laso, A., Fernández, X., Landa, J. I. G., & Palomo, C. (2017) · ChemBioChem · doi:10.1002/cbic.201600642 · Cited by 3
Chakraborty, S., Das, S., Chakravarty, R., Sarma, H. D., Vatsa, R., Shukla, J., Mittal, B. R., & Dash, A. K. (2019) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3786 · Cited by 3
Collyer, S. E., Stack, G. D., & Walsh, J. J. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220401105929 · Cited by 2
Ultrasensitive detection of uveal melanoma using [18F]AlF-NOTA-PRGD2 PET imaging
Wang, L., Zhu, X., Xue, Y., Huang, Z., Zou, W., Zhang, Z., Yu, M., Pan, D., & Wang, K. (2024) · EJNMMI Research · doi:10.1186/s13550-024-01123-4 · Cited by 2
Quantum dot800-poly(ethylene glycol)-c(Arg-Gly-Asp-d-Tyr-Lys)
Leung, K. (2011) · Europe PMC (PubMed Central) · Cited by 2
Rossetti, A., Travaglia, T., Rossini, P., Odeh, M., Arru, L., & Ragni, F. (2011) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2011.01.002 · Cited by 2
Abou-Shamaa, L. A., & Mahmoud, G. N. (2008) · PubMed · Cited by 3
RGD mimetics γ-AApeptides and methods of use (US 20,140,004,039 A1): a patent evaluation
Wu, H., Jiang, J., Xu, H., Li, Q., & Cai, J. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1111337 · Cited by 2
Cell Recruitment and Angiogenesis
Szekanecz, Z., & Koch, A. E. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00025-6 · Cited by 2
Das, S., Sahu, S., Chakraborty, A., Kamaleshwaran, K. K., Upadhye, T. S., Damle, A. A., Chakravarty, R., & Chakraborty, S. (2023) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2023.110725 · Cited by 1
Goswami, S., Thompson, L. C., Wickman, L., & Peterson, C. B. (2013) · Advances in Biological Chemistry · doi:10.4236/abc.2013.31015 · Cited by 1
Leung, K. (2012) · Europe PMC (PubMed Central) · Cited by 1
Cyclo(Arg-Gly-Asp-D-Try-Glu) conjugated to ultrasmall superparamagnetic iron oxide nanoparticles
Leung, K. (2008) · Cited by 1
Lu, X., Peng, H., Zhiqiang, L., & Xiaoli, Z. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2017.01.013 · Cited by 1
Influence of the Bone Microenvironment on Breast Cancer Metastasis to Bone
Eckhardt, B. L., Pouliot, N., & Anderson, R. L. (2005) · Springer eBooks · doi:10.1007/1-4020-3414-8_8 · Cited by 1
Cloning and biological activity of an anti-tumor peptide of Tumstatin
Wang, S., Liu, Y., Lin, X., Fu, X., Xu, J., & Liu, X. (2007) · Frontiers in Biology · doi:10.1007/s11515-007-0040-4 · Cited by 1
Nanotechnologies for Targeted Delivery of Drugs
Brož, P., & Hunziker, P. (2003) · Wiley eBooks · doi:10.1002/9783527610419.ntls0111 · Cited by 1
[18F]Fluorobenzyl-bombesin[7-14]-c(RGDyK)
Leung, K. (2008) · National Center for Biotechnology Information (US) eBooks
Mas‐Moruno, C., & Kessler, H. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527648207.ch11
Indocyanine green derivative 02-Glu-c(RGDyK)2
Leung, K. (2012) · Europe PMC (PubMed Central)
Integrin-ligand interactions and cytokine production by monocytic cells
Edkins, A. L. (2008) · Enlighten: Theses (The University of Glasgow)
Ahmadi, M. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 3
Küsters, B. (2006) · Radboud Repository (Radboud University)
PET Imaging of Tumor Integrin Expression
Cai, W., & Chen, X. S. (2006) · IEEE Computational Systems Bioinformatics Conference (CSB) · doi:10.1109/csbw.2005.105
A Role for Integrin avß3 in Invasion Activity of Highly Metastatic Syrian Hamster Fibroblasts
Berman, A. E., Kozlova, N. E., & Morozevich, G. E. (2004) · Technische Universität Dortmund Eldorado (Technische Universität Dortmund) · doi:10.17877/de290r-119
64Cu-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-cyclo(Arg-Gly-Asp-d-Phe-Lys)
Leung, K. (2012) · Europe PMC (PubMed Central)
Cyclo(Cys-Arg-Gly-Asp-Cys)-Gly-Lys-Cy5.5
Leung, K. (2012) · Europe PMC (PubMed Central)
Leung, K. (2007) · Europe PMC (PubMed Central)
Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys/Cy5.5-Ferritin 64Cu-loaded nanocages
Leung, K. (2011) · National Center for Biotechnology Information (US) eBooks
123I-c(RGDfK)-human serum albumin-tissue inhibitor of matrix metalloproteinase 2 fusion protein
Leung, K. (2012) · Europe PMC (PubMed Central)
N-4-[18F]Fluorobenzoyl-c(RGDyK)
Leung, K. (2008) · Europe PMC (PubMed Central)
99mTc(CO)3-Bipyridine-cyclo-(Arg-Gly-Asp-D-Tyr-Lys)
Leung, K. (2007) · Europe PMC (PubMed Central)
[99mTc-Gly-Gly-Cys]-Ornithine-ornithine-ornithine-cyclo(Arg-Gly-Asp-d-Phe-Lys)
Leung, K. (2013) · Europe PMC (PubMed Central)
Leung, K. (2012) · Europe PMC (PubMed Central)
4-[18F]Fluorobenzoyl-NAVPNLRGDLQVLAQKVART
Leung, K. (2008) · Europe PMC (PubMed Central)
111In-Diethylenetriamine pentaacetic acid-NAVPNLRGDLQVLAQKVART
Leung, K. (2012) · Europe PMC (PubMed Central)
99mTc-Hydrazinonicotinyl(tricine)(TPPTS)-Glu-c(RGDyK)-bombesin[7-14]NH2
Leung, K. (2012) · Europe PMC (PubMed Central)
64Cu-1,4,7,10-Tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid-iron oxide-c(RGDyK) nanoparticles
Leung, K. (2009) · Europe PMC (PubMed Central)
Transcriptomic and proteomic approaches to the discovery of new markers of pathology
Elia, G. (2005) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-a-005151527
99mTc-Glucosamino-Asp-cyclo(Arg-Gly-Asp-D-Phe-Lys)
Leung, K. (2007)
Identification of proteomic biomarkers for the prediction of implant biological responses
Gavilán, F. J. R. (2018) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14107.2018.209264 · Cited by 1
Prostate cancer: Delivery aspect and prospect
Jain, S., Raza, K., Agrawal, A. K., & Vaidya, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817846-1.00024-2
Cartilage type IIB procollagen NH2-propeptide, PIIBNP, inhibits angiogenesis
Wang, Z., & Lu, A. (2021) · AIMS molecular science · doi:10.3934/molsci.2021022
Cyclo(Arg-Gly-Asp-d-Tyr-Lys)-Cy5.5
Leung, K. (2011) · Europe PMC (PubMed Central)
Cypate-Gly-Arg-Asp-Ser-Pro-Lys
Leung, K. (2005) · Europe PMC (PubMed Central)
Zheng, L., Duan, S., Li, Y., Che, H., Liang, Y., Zhang, X., Lin, B., Li, C., Deng, J., Qiu, X., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10575289/v1
The novel [ 68 Ga]Ga-DOTA-C6-anti-integrin peptide in glioblastoma
Carron, J., Melo, G. F., da Silva, F. F. A., Alves, F. L., Santos, M. E. D. O. A., Rodrigues, V. P. D. C., Ali, A., Franchi, G. C., de Carvalho, J. E., Ruiz, A. L. T. G., et al. (2026) · RSC Advances · doi:10.1039/d6ra07459f
BindingDB Entry 50015753: Sortase A-mediated cyclization of novel polycyclic RGD peptides for α
BindingDB (2023) · UC San Diego · doi:10.7270/q2xs60c4
[18F]Fluorobenzyl-PEG3-Glu-c(RGDyK)-bombesin[7-14]
Leung, K. (2009)
Metadata
- Authors
- Kumar, C.
- Corresponding author
- Kumar, C.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-02-01
- Volume
- 4
- Issue
- 2
- Pages
- 123-131
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W147592962
- Cited by
- 280
- References
- 0
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 6 · 2022: 14 · 2021: 4 · 2020: 9 · 2019: 11 · 2018: 8 · 2017: 9 · 2016: 8 · 2015: 11 · 2014: 11 · 2013: 20 · 2012: 20
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Keywords
- integrin αvβ3, tumor angiogenesis, angiogenesis inhibitors, monoclonal antibodies, small molecule antagonists, angiostatin, endostatin, tumstatin, tumor growth, metastasis, bone metastasis, osteoclast resorption, rheumatoid arthritis, osteoporosis, therapeutic target
- MeSH terms
- Animals, Humans, Neoplasms, Neovascularization, Pathologic, Drug Delivery Systems, Angiogenesis Inhibitors, Integrin alphaVbeta3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.